Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · IEX Real-Time Price · USD
0.428
+0.012 (2.89%)
At close: Jul 26, 2024, 3:55 PM
0.430
+0.002 (0.47%)
After-hours: Jul 26, 2024, 7:36 PM EDT
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $305.72K in the quarter ending March 31, 2024, a decrease of -61.28%. This brings the company's revenue in the last twelve months to $1.75M, down -35.55% year-over-year. In the year 2023, Ensysce Biosciences had annual revenue of $2.23M, down -11.61%.
Revenue (ttm)
$1.75M
Revenue Growth
-35.55%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
3.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
Dec 31, 2020 | 3.93M | 2.17M | 122.86% |
Dec 31, 2019 | 1.76M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xylo Technologies | 91.72M |
NovaBay Pharmaceuticals | 14.23M |
Petros Pharmaceuticals | 4.69M |
INVO Bioscience | 4.25M |
Fresh2 Group | 2.35M |
Akanda | 2.16M |
ENSC News
- 4 days ago - Ensysce Biosciences Provides Mid-Year 2024 Update - Accesswire
- 18 days ago - Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset - Accesswire
- 4 weeks ago - Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting - Accesswire
- 4 weeks ago - Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate - Accesswire
- 7 weeks ago - Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program - Accesswire
- 7 weeks ago - Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting - Accesswire
- 2 months ago - Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform - Accesswire
- 2 months ago - Ensysce Biosciences Reports First Quarter 2024 Financial Results - Accesswire